ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis

Journal of Clinical Investigation

Volumn 124, Issue 6, 2014, Pages 2626-2639

  Condamine, Thomas ^a   Kumar, Vinit ^a   Ramachandran, Indu R ^a   Youn, Je In ^a   Celis, Esteban ^b,h   Finnberg, Niklas ^c   El Deiry, Wafik S ^c   Winograd, Rafael ^d   Vonderheide, Robert H ^d   English, Nickolas R ^e   Knight, Stella C ^e   Yagita, Hideo ^f   McCaffrey, Judith C ^b   Antonia, Scott ^b   Hockstein, Neil ^g   Witt, Robert ^g   Masters, Gregory ^g   Bauer, Thomas ^g   Gabrilovich, Dmitry I ^a  

^a WISTAR INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c PENN STATE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f JUNTENDO UNIVERSITY   (Japan)

^g HELEN F GRAHAM CANCER CENTER   (United States)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CELL EXPANSION; CELL FATE; CELL ISOLATION; CELL POPULATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MOLECULAR PATHOLOGY; MONOCYTE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SUPPRESSOR CELL;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MYELOID CELLS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84902162433     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74056     Document Type: Article

References (53)

1. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-268.
2. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumorbearing mice. J Immunol. 2008;181(8):5791-5802.
3. Movahedi K, et al. Identification of discrete tumorinduced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity. Blood. 2008;111(8):4233-4244.
4. Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91(1):167-181.
5. Peranzoni E, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22(2):238-244.
6. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32(1):19-25.
7. Sonda N, Chioda M, Zilio S, Simonato F, Bronte V. Transcription factors in myeloid-derived suppressor cell generation. Curr Opin Immunol. 2011;23(2):279-285.
8. Zhao X, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 2012;122(11):4094-4104.
9. Roth F, De La Fuente AC, Vella JL, Zoso A, Inverardi L, Serafini P. Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression. Cancer Res. 2012;72(6):1373-1383.
10. Hu X, et al. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer. J Biol Chem. 2013;288(26):19103-19115.
11. Chornoguz O, Grmai L, Sinha P, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Molecular & cellular proteomics: MCP. 2011;10(3):M110002980.
12. Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Myeloidderived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 2011;117(20):5381-5390.
13. Youn JI, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol. 2013;14(3):211-220.
14. Rudel T. Caspase inhibitors in prevention of apoptosis. Herz. 1999;24(3):236-241.
15. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205-219.
16. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature reviews. Cancer. 2008;8(10):782-798.
17. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets. 2010;14(10):1091-1108.
18. Emery JG, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273(23):14363-14367.
19. Finnberg N, et al. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol. 2005;25(5):2000-2013.
20. Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest. 2008;118(1):111-123.
21. Janssen EM, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activationinduced cell death. Nature. 2005;434(7029):88-93.
22. Roberts AI, et al. The role of activation-induced cell death in the differentiation of T-helper-cell subsets. Immunol Res. 2003;28(3):285-293.
23. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
24. Cazanave SC, et al. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem. 2011;286(45):39336-39348.
25. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007;39(7-8):1462- 1475.
26. Tian X, Ye J, Alonso-Basanta M, Hahn SM, Koumenis C, Dorsey JF. Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem. 2011;286(33):29408-29416.
27. Martin-Perez R, Niwa M, Lopez-Rivas A. ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis. 2012;17(4):349-363.
28. Tiwary R, Yu W, Li J, Park SK, Sanders BG, Kline K. Role of endoplasmic reticulum stress in α-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One. 2010;5(7):e11865.
29. Liu G, et al. Salermide up-regulates death receptor 5 expression through the ATF4-ATF3-CHOP axis and leads to apoptosis in human cancer cells. J Cell Mol Med. 2012;16(7):1618-1628.
30. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13(2):89-102.
31. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011;11(7):802-807.
32. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother. 2012;35(2):107-115.
33. Ko JS, et al. Sunitinib mediates reversal of myeloidderived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148-2157.
34. Ozcan U, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137- 1140.
35. Ilkovitch D, Lopez DM. The liver is a site for tumorinduced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res. 2009;69(13):5514-5521.
36. Chen S, Akbar SM, Abe M, Hiasa Y, Onji M. Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin Exp Immunol. 2011;166(1):134-142.
37. Swirski FK, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325(5940):612-616.
38. Cortez-Retamozo V, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A. 2012;109(7):2491-2496.
39. Ribechini E, Leenen PJ, Lutz MB. Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. Eur J Immunol. 2009;39(12):3538-3551.
40. Walczak H, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature medicine. 1999;5(2):157-163.
41. Haynes NM, et al. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol. 2010;185(1):532-541.
42. Takeda K, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med. 2004;199(4):437-448.
43. Clancy L, et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A. 2005;102(50):18099-18104.
44. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006;26(19):7046-7055.
45. Shetty S, et al. Transcription factor NF-κB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol. 2005;25(13):5404-5416.
46. Shiraishi T, et al. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis in human prostate cancer cells. Cancer Res. 2005;65(14):6364-6370.
47. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334(6059):1081-1086.
48. Huang L, Xu J, Li K, Zheng MH, Kumta SM. Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone. Bone. 2004;34(6):971-981.
49. Santos CX, Tanaka LY, Wosniak J, Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal. 2009;11(10):2409-2427.
50. Fu S, Watkins SM, Hotamisligil GS. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab. 2012;15(5):623-634.
51. Herber DL, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010;16(8):880-886.
52. Bayne LJ, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012;21(6):822-835.
53. Nagaraj S, Nelson A, Youn JI, Cheng P, Quiceno D, Gabrilovich DI. Antigen-specific CD4 (+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res. 2012;72(4):928-938.